Craneware
1850p
25.0 1.4%
market vs.
industry Growth & Value
| 12m Forecast Rolling | ||||
| PE Ratio (f) | 39.5 |
|
|
|
| PEG Ratio (f) |
|
|
||
| EPS Growth (f) | % |
|
|
|
| Dividend Yield (f) | % |
|
|
|
| Valuation (ttm) | ||||
| Price to Book Value | 10.5 |
|
|
|
| Price to Tang. Book |
|
|
||
| Price to Free Cashflow |
|
|
||
| Price to Sales |
|
|
||
| EV to EBITDA |
|
|
||
market vs.
industry Quality
| Year End 30th Jun | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | TTM | 2018E | 2019E | CAGR / Avg | |
| Revenue | $m | ||||||||||
| Operating Profit | $m | ||||||||||
| Net Profit | $m | ||||||||||
| EPS Reported | $ | ||||||||||
| EPS Normalised | $ | ||||||||||
| EPS Growth | % | ||||||||||
| PE Ratio | x | ||||||||||
| PEG | x | ||||||||||
| Profitability | |||||||||||
| Operating Margin | % | ||||||||||
| ROA | % | ||||||||||
| ROCE | % | ||||||||||
| ROE | % | ||||||||||
| Cashflow | |||||||||||
| Op. Cashflow ps | $ | ||||||||||
| Capex ps | $ | ||||||||||
| Free Cashflow ps | $ | ||||||||||
| Last ex-div: 29th Mar, paid: 20th Apr more... Dividends | |||||||||||
| Dividend ps | $ | ||||||||||
| Dividend Growth | % | ||||||||||
| Dividend Yield | % | ||||||||||
| Dividend Cover | x | ||||||||||
| Balance Sheet | |||||||||||
| Cash etc | $m | ||||||||||
| Working Capital | $m | ||||||||||
| Net Fixed Assets | $m | ||||||||||
| Net Debt | $m | ||||||||||
| Book Value | $m | ||||||||||
| Average Shares | m | ||||||||||
| Book Value ps | $ | +9.7% | |||||||||
| Leverage (ttm) | Total | -Intang | +Pension | ||
| Gross Gearing | % | ||||
| Net Gearing | % | ||||
| Cash / Assets | % |
| Liquidity (ttm) | ||
| Curr. Ratio | ||
| Quick Ratio | ||
| Interest Cov. | ||
| Efficiency (ttm) | |
| Asset Turnover | |
| Rec's Turnover | |
| Stock Turnover | |
market vs.
industry Recent History
| Latest interim period (ended 31st Dec '17) vs. prior year | ||||
| Sales Growth | % |
|
|
|
| EPS Growth | % |
|
|
|
| 3yr Compound Annual Growth Rate | ||||
| Sales Growth | % |
|
|
|
| EPS Growth | % |
|
|
|
| DPS Growth | % |
|
|
|
Broker Consensus Trend
| Recommendation: | Strong Sell | Sell | Hold | Buy | Strong Buy |
|---|---|---|---|---|---|
| No. of Analysts: | 0 | 0 | 1 | 0 | 2 |
Craneware plc is a United Kingdom-based company, which is engaged in the development, licensing and ongoing support of computer software for the United States healthcare industry. The Company's Value Cycle Solutions span over five product families, which include Patient Engagement, Charge Capture & Pricing, Coding Integrity, Cost Analytics, and Revenue Collection & Retention. Its Patient Engagement solutions include InSight Medical Necessity, Trisus Patient Payment and Patient Charge Estimator. The Charge Capture & Pricing solutions include Chargemaster Toolkit Discovery Viewer; Physician Revenue Toolkit, Physician Management Toolkit and Physician Revenue Toolkit-Corporate; Pricing Analyzer; Reference Plus; Pharmacy ChargeLink; Supplies ChargeLink, and Supporting Modules. Its Coding Integrity solutions include Trisus Claims Informatics and Bill Analyzer. Its Revenue Recovery & Retention solutions include InSight Audit and InSight Denials. It also offers professional services.
Directors: Keith Neilson (CEO) 48, Craig Preston (CFO) 46, George Elliot (NEC) 64, Colleen Blye (NED) 57, Russ Rudish (NED) 65, Ronald Verni (NID) 69,
No. of Employees: 263 No. of Shareholders: n/a
| Last Annual | June 30th, 2017 |
| Last Interim | December 31st, 2017 |
| Incorporated | May 19, 1999 |
| Public Since | September 13, 2007 |
| Shares in Issue | 26,662,271 |
| Free Float | 19.2m (72.2%) |
| Sector | Healthcare |
| Industry | Healthcare Equipment & Supplies |
| Index | FTSE Aim All Share , FTSE Aim 100 , |
| Exchange |
London Stock Exchange (AIM)
|
| Eligible for | an ISA? a SIPP? |
| Address | 1 Tanfield, EDINBURGH, EH3 5DA, United Kingdom |
| Web | https://public.craneware.com/ |
| Phone | +44 131 5503100 |
| Contact | () |
| Auditors | PricewaterhouseCoopers LLP |
Recent ↓
Use of our data service is subject to express Terms of Service. Please see our full site disclaimer for more details. In particular, it is very important to do your own research (DYOR) and seek professional advice before making any investment based on your own personal circumstances. Please note that the information, data and analysis contained within this stock report: (a) include the proprietary information of Stockopedia's third party licensors and Stockopedia; (b) should not be copied or redistributed except as specifically authorised; and (c) are not warranted to be complete, accurate or timely. You should independently research and verify any information that you find in this report. Stockopedia will not be liable in respect of any loss, trading or otherwise, that you may suffer arising out of such information or any reliance you may place upon it. Past performance is no guarantee of future results. The value and income derived from investments may go down as well as up. © Stockopedia 2018.
